About

Partnering

• Zumutor has developed a fully human proprietary mAb technology platform (INABLR™) that facilitated rapid identification of selective and potent mAbs with potential to enhance ADCC activity
• ZM008 is a fully human IgG1 which blocks the interaction between LLT1(on tumor cell) and CD161(on NK), there by activating NK cell and the downstream tumor killing MOA has been established
• Our partnerships with leading clinical centers like Mt Sinai-NYC and other hospital groups for patient centric data approaches validates our robust approach for ensuing Phase 1 studies
• Zumutor looks to drive value driven opportunities of licensing the asset (currently preclinical) in multiple geographies
• Zumutor looks to partner and collaborate for other immuno-onco targets that could drive novel Ab hits through the INABLR™ platform
• We are actively seeking opportunities to partner development of bispecifics/ CART/ CAR-NK molecules using our proprietary antibody discovery platforms to fast-track development
• We offer flexible- full service bespoke services for analytical and process development

For information on partnering and collaborations, please write to [email protected]

–

Syngene International, a leading global Contract Research Services Company, has entered into a non-exclusive partnering agreement with Zumutor Biologics, an emerging immunooncology Company, to access Zumutor’s proprietary naïve human phage/yeast display library. This collaboration further enhances Syngene’s market-leading capabilities in Discovery Biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery

–

On 12 November, 2019 Zumutor Biologics and Prof. Vijay Kuchroo Laboratory (Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital Ann Romney Center for Neurologic Diseases) have inked an agreement to discover unique human monoclonal antibodies against a novel cytokine identified by Kuchroo Laboratory. Zumutor will use its proprietary antibody discovery platform INABLR® to identify novel antibody clones against the cytokine

–

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has signed an agreement with Zumutor Biologics, Inc., to manufacture Zumutor’s lead candidate, ZM008, for the treatment of solid tumors